

Contact: Zeid Barakat
CEO, BiomaRx Inc.
Phone: 917.363.3438
zeid@biomarx.com



PRESS RELEASE

BiomaRx Strikes Collaborative Agreement with SBH Sciences and Woodland Biosciences

Cambridge, MA, February 16, 2017: BiomaRx reached a collaborative development and investment agreement with SBH Sciences and Woodland Biosciences, for capital applied to services in kind, dedicated laboratory facilities, and access to the CLIA certified/CAP accredited laboratory.

As part of the creative collaboration agreement, both Michael Briggs, PhD, and Raphael Nir, PhD, will join the Advisory Board of BiomaRx. Michael Briggs, President & CSO of Woodland Biosciences and a former Sr. Director at Vertex, brings over 20 years of biotech leadership experience developing novel oncology models and anti-cancer therapeutics. Raphael Nir, an entrepreneur and angel investor, is co-founder of Karyopharm Therapeutics, Woodland Biosciences, Galectin Sciences, and Alma Bio-Therapeutics. Additionally, he is co-founder of SBH Sciences where he is the President and Chief Scientific Officer.

"We believe in BiomaRx and have confidence that this technology will make a significant contribution to the earlier diagnosis of pancreatic cancer and thus save lives. We are pleased to be part of this collaboration and look forward to working together" said Raphael Nir.

"This is a great opportunity to leverage the world class expertise and facilities of both SBH and Woodland. Raphael and Michael bring deep insights that will help us develop and commercialize a first-ever non-invasive diagnostic for pancreatic cancer", said Zeid Barakat, CEO of BiomaRx. "The SBH and Woodland partnership with BiomaRx is an exciting first-step in helping us to transition this promising life-saving technology from the academic lab to a CLIA certified/CAP accredited one, with all of the resources of a commercial facility" added Roya Khosravi-Far, Co-Founder and Chief Scientific Officer at BiomaRx. "We are excited to get going!"

SBH Sciences, based in Natick, MA offers a suite of services, including 10 biomarker platforms, to help accelerate BiomaRx diagnostic and therapeutic development programs. These facilities include two state-of-the-art cell culture labs, a protein purification lab, a molecular biology lab, and a CLIA certified/CAP accredited lab. Woodland Biosciences is located in Grafton, MA and offers an assemblage of *in vivo* services for the study of metabolic diseases and oncology, including orthotopic xenografts for pancreas cancers.

Based out of Cambridge, MA, BiomaRx is a seed-stage venture focused on making pancreatic cancer a treatable condition through early diagnosis. The team is developing a non-invasive diagnostic for pancreatic cancer, a disease that is projected to be the second leading cancer killer by 2020. Spun out of Harvard Medical School and Beth Israel Deaconess Medical Center, BiomaRx uses a proprietary systems biology engine to identify next-gen diagnostic biomarkers and therapeutic targets for first-in class pancreatic cancer diagnosis and treatment.